Dosage Forms & Drug Delivery Systems – Page 48

Fine Particle Fraction Drift during EU/UK launch supply: FDA/MHRA investigation and corrective actions

Recognizing symptoms or signals indicative of fine particle fraction drift is crucial for timely intervention. Operators and quality control personnel should remain vigilant for the following signals:Click to read the…

E&L Failure for nanoformulations: control strategy build-out for inspections

Identifying signals of an E&L failure is crucial for taking immediate action. Symptoms may manifest in various ways, such as:Click to read the full article.

Stability Failure during tech transfer: risk assessment and change control template

Recognizing early warning signs of stability failure is essential for prompt remediation. Symptoms can vary but commonly include:Click to read the full article.

Delivered Dose Uniformity Failure during inspection preparation: method variability vs true product failure assessment

The first step in addressing a delivered dose uniformity failure is identifying and documenting symptoms observed on the manufacturing floor or in the laboratory. Key symptoms include:Click to read the…

Oos Investigation for combination drug products: batch release impact and documentation pack

The identification of OOS results can arise from several sources in manufacturing or laboratory settings. Symptoms may include but are not limited to:Click to read the full article.

Design Controls Deficiency during FDA inspection: what inspectors expect and how to fix it

The first step in addressing design controls deficiencies is identifying the symptoms or signals that indicate a potential issue. Symptoms include, but are not limited to:Click to read the full…

Human Factors Validation Failure for drug-device combination products: what inspectors expect and how to fix it

Identifying symptoms and signals is the initial step in investigating human factors validation failures. Symptoms may include:Click to read the full article.

E&L Failure during method transfer: E&L risk assessment and documentation

E&L Risk Assessment and Documentation for Method Transfer Failures In the realm of pharmaceutical manufacturing, Extractables and Leachables (E&L) assessments are critical in ensuring safety and quality. However, during method…

Complaint Handling Deficiency for combination drug products: what inspectors expect and how to fix it

Detecting symptoms or signals that suggest a complaint handling deficiency is crucial. Common scenarios include:Click to read the full article.

Design Controls Deficiency for combination drug products: CAPA plan with effectiveness checks

Identifying symptoms of potential design controls deficiencies is the first step in the investigation process. Symptoms might manifest as unexpected deviations, quality complaints, or analytical failures upon product testing. Common…

Delivered Dose Uniformity Failure during EU/UK launch supply: method variability vs true product failure assessment

The first step in addressing a Delivered Dose Uniformity failure is recognizing the symptoms or signals that indicate a potential problem. Common indicators include:Click to read the full article.

Supplier Qualification Gap for drug-device combination products: ownership between drug GMP and device QMS

Identifying symptoms is crucial for initiating an investigation into supplier qualification gaps. Common signals include:Click to read the full article.